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A B S T R A C T
Background
Endometrial cancer is one of the most common gynaecological cancers in the world. Rates of endometrial cancer are rising, in part
because of rising obesity rates. Endometrial hyperplasia is a precancerous condition in women that can lead to endometrial cancer if
left untreated. Endometrial hyperplasia occurs more commonly than endometrial cancer. Progesterone tablets currently used to treat
women with endometrial hyperplasia are associated with adverse effects in up to 84% of women. The levonorgestrel intrauterine
device (Mirena Coil, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA) may improve compliance, but it is invasive, is not
acceptable to all women, and is associated with irregular vaginal bleeding in 82% of cases. Therefore, an alternative treatment for women
with endometrial hyperplasia is needed. Metformin, a drug that is often used to treat people with diabetes, has been shown in some
human studies to reverse endometrial hyperplasia. However, the effectiveness and safety of metformin for treatment of endometrial
hyperplasia remain uncertain.
Objectives
To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia.
Search methods
We searched the Cochrane Gynaecology and Fertility Specialised Register, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, Google Scholar,
OpenGrey, Latin American Caribbean Health Sciences Literature (LILACS), and two trials registers from inception to 10 January
2017. We searched the bibliographies of all included studies and reviews on this topic. We also handsearched the conference abstracts of
the European Society of Human Reproduction and Embryology (ESHRE) 2015 and the American Society for Reproductive Medicine
(ASRM) 2015.
Selection criteria
We included randomised controlled trials (RCTs) and cross-over trials comparing metformin (used alone or in combination with other
medical therapies) versus placebo or no treatment, any conventional medical treatment, or any other active intervention for women
with histologically confirmed endometrial hyperplasia of any type.
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Data collection and analysis
Two review authors independently assessed studies for eligibility, extracted data from included studies, and assessed the risk of bias of
included studies. We resolved disagreements by discussion or by deferment to a third review author. When study details were missing,
review authors contacted study authors. The primary outcome of this review was regression of endometrial hyperplasia histology (with
or without atypia) towards normal histology. Secondary outcome measures included recurrence of endometrial hyperplasia, progression
of endometrial hyperplasia to endometrial cancer, hysterectomy rate, abnormal uterine bleeding, health-related quality of life, and
adverse effects during treatment.
Main results
We included three RCTs in which a total of 77 women took part. We rated the quality of the evidence as very low for all outcomes
owing to very serious risk of bias (associated with poor reporting, attrition, and limitations in study design) and imprecision.
We performed a meta-analysis of two trials with 59 participants. Whenmetformin was compared with megestrol acetate in women with
endometrial hyperplasia, we found insufficient evidence to determine whether there were differences between groups for the following
outcomes: regression of endometrial hyperplasia histology towards normal histology (odds ratio (OR) 3.34, 95% confidence interval
(CI) 0.97 to 11.57, two RCTs, n = 59, very low-quality evidence), hysterectomy rates (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n =
59, very low-quality evidence), and rates of abnormal uterine bleeding (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 44 , very low-
quality evidence). We found no data for recurrence of endometrial hyperplasia or health-related quality of life. Both studies (n = 59)
provided data on progression of endometrial hyperplasia to endometrial cancer as well as one (n = 16) reporting some adverse effects
in the metformin arm, notably nausea, thrombosis, lactic acidosis, abnormal liver and renal function among others.
Another trial including 16 participants compared metformin plus megestrol acetate versus megestrol acetate alone in women with
endometrial hyperplasia. We found insufficient evidence to determine whether there were differences between groups for the following
outcomes: regression of endometrial hyperplasia histology towards normal histology (OR 9.00, 95% CI 0.94 to 86.52, one RCT, n =
16, very low-quality evidence), recurrence of endometrial hyperplasia among women who achieve regression (OR not estimable, no
events recorded, one RCT, n = 8, very low-quality evidence), progression of endometrial hyperplasia to endometrial cancer (OR not
estimable, no events recorded, one RCT, n = 13, very low-quality evidence), or hysterectomy rates (OR 0.29, 95% CI 0.01 to 8.37,
one RCT, n = 16, very low-quality evidence). Investigators provided no data on abnormal uterine bleeding or health-related quality of
life. In terms of adverse effects, three of eight participants (37.5%) in the metformin plus megestrol acetate study arm reported nausea.
Authors’ conclusions
At present, evidence is insufficient to support or refute the use of metformin alone or in combination with standard therapy - specifically,
megestrol acetate - versus megestrol acetate alone, for treatment of endometrial hyperplasia. Robustly designed and adequately powered
randomised controlled trials yielding long-term outcome data are needed to address this clinical question.
P L A I N L A N G U A G E S U M M A R Y
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Review question
Is metformin an effective and safe treatment for people with endometrial hyperplasia?
Background
Endometrial cancer (cancer of the lining of the womb) is a common cancer that affects the reproductive organs in women worldwide.
Endometrial hyperplasia is a precancerous condition in women that can lead to endometrial cancer, if left untreated. Successful treatment
of women with endometrial hyperplasia can prevent endometrial cancer. Endometrial hyperplasia is usually treated by providing
progesterone hormone tablets, inserting the levonorgestrel intrauterine system (Mirena Coil) into the womb, advising overweight
women to lose weight, or performing a hysterectomy for women who do not want any future pregnancy. However, progesterone tablets
are associated with side effects in up to 84% of women, and this can prevent women from completing treatment. Also, progesterone
tablets do not always work, and endometrial hyperplasia can return in up to 14% to 30% of women after treatment. The Mirena Coil
is associated with irregular vaginal bleeding in up to 82% of women, and many women find it painful to use or otherwise unacceptable.
Therefore, an alternative treatment for endometrial hyperplasia is required. Metformin, an oral tablet that usually is used to treat
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diabetes, has been shown to cure endometrial hyperplasia in some human studies. Although people taking metformin may experience
side effects, treatment is usually well tolerated. If women experience fewer side effects when taking metformin rather than progesterone
tablets, and if metformin effectively treats endometrial hyperplasia, then compliance will be better and the cure rate will improve. This
could reduce the number of women who end up with endometrial cancer. However, the effectiveness and safety of metformin used to
treat women with endometrial hyperplasia remain uncertain.
Study characteristics
We included three randomised controlled trials in which a total of 77 women took part. Two studies compared metformin versus
megestrol acetate (a form of progesterone), and one study compared metformin plus megestrol acetate versus megestrol acetate alone.
Women in all studies received treatment for approximately 12 weeks. The evidence is current to 10 January 2017.
Key results
Comparisons of metformin versus megestrol acetate have provided insufficient evidence to show differences in effectiveness for curing
endometrial hyperplasia. It remains uncertain whether there is any difference between metformin and megestrol acetate in reducing
hysterectomy rates or abnormal uterine bleeding in women with endometrial hyperplasia. Although both studies provided data on
progression of endometrial hyperplasia to endometrial cancer, there were no events in either arm, and study authors reported no data
on adverse effects.
When metformin plus megestrol acetate is compared with megestrol acetate, differences in effectiveness between groups treating
endometrial hyperplasia remain unclear. Three of eight patients in the metformin plus megestrol acetate study arm reported nausea.
Occurrence of other adverse events is unclear.
Quality of the evidence
We rated the quality of evidence as very low for all outcomes owing to very serious risk of bias (associated with poor reporting, attrition,
and limitations in study design) and imprecision.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Metformin compared with megestrol acetate for endometrial hyperplasia
Patient or population: women with endometrial hyperplasia
Setting: hospital outpat ient clinic
Intervention: metform in
Comparison: megestrol acetate
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk withmegestrol ac-
etate
Risk with metformin
Regression of endome-
trial hyperplasia (with
or without atypia) to-
wards normal histology
Assessed by histologi-
cal examinat ion
Follow-up: 3 months
615 per 1000 842 per 1000
(608 to 949)
OR 3.34
(0.97 to 11.57)
59
(2 RCTs)
⊕©©©
VERY LOWa,b
Normal histology is de-
f ined as atrophic or pro-
lif erat ive endometrium
Recurrence of endome-
trial hyperplasia
See comment Not est imable (0 studies) - No data for recurrence
of endometrial hyper-
plasia for this compari-
son
Progression of en-
dometrial hyperplasia
to endometrial cancer
Assessed by histologi-
cal examinat ion
Follow-up: 3 months
0 per 1000 0 per 1000
(0 to 0)
Not est imable 59
(2 RCTs)
⊕©©©
VERY LOWc,d
Hysterectomy rate
Follow-up: 3 months
37 per 1000 34 per 1000
(2 to 374)
OR 0.91
(0.05 to 15.52)
61
(2 RCTs)
⊕©©©
VERY LOWc,e
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Abnormal uterine
bleeding
Assessed by self -report
Follow-up: 3 months
48 per 1000 44 per 1000
(2 to 437)
OR 0.91
(0.05 to 15.52)
44
(1 RCT)
⊕©©©
VERY LOWb,f
Health-related quality
of lif e (HRQL)
See comment Not est imable (0 studies) - No data for HRQL for
this comparison
Adverse ef fects during
treatment
See comment Not est imable (0 studies) - No data for adverse ef -
fects during treatment
for this comparison,
with the except ion of
abnormal uterine bleed-
ing (see above)
*The risk in the intervention group (and its 95%conf idence interval) is based on mean risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io.
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by two levels for very serious risk of bias: One study was an open-label study; the other did not detail random
sequence generat ion or allocat ion concealment or blinding; inadequately applied its inclusion criteria to study part icipants;
and was at high risk of attrit ion bias.
bDowngraded by two levels for very serious imprecision: Both studies have very small sample sizes, and conf idence intervals
are compatible with a large ef fect in either group or with null ef fect.
cDowngraded by two levels for very serious risk of bias: One study was an open-label study; the other did not detail random
sequence generat ion or allocat ion concealment or blinding; inadequately applied its inclusion criteria to study part icipants;
and was at high risk of attrit ion bias. We had concern about inadequate follow-up t ime to detect this outcome.
dDowngraded by two levels for very serious imprecision: Inadequate sample size to capture a relat ively uncommon event over
too short a period means that conf idence intervals could not be generated for this outcome.
eDowngraded by two levels for very serious imprecision: Both studies have an inadequate sample size studied over too short
a period, and conf idence intervals are compatible with a large ef fect in either group or with null ef fect.
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fDowngraded by two levels for very serious risk of bias: The included study was an open-label study that recorded only
abnormal uterine bleeding that was self -reported.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Endometrial hyperplasia is a precancerous endometrial lesion that
commonly presents with abnormal uterine bleeding. It is thought
to be due to unopposed, prolonged exposure of the endometrium
to oestrogen and, if managed expectantly, can progress to en-
dometrial carcinoma, although the condition may resolve sponta-
neously. It is diagnosed histologically and subsequently can be cat-
egorised into four subtypes: simple, simple with atypia, complex,
and complex with atypia (Kurman 1985). Risk of progression to
endometrial carcinoma is dependent on the type of endometrial
hyperplasia, and progression rates vary widely across the literature.
This discrepancy is likely due, in part, to the fact that many cases
of endometrial hyperplasia, especially when atypia is present, are
managed pre-emptively with a hysterectomy. However, atypia is
thought to be a strong risk factor for progression to adenocar-
cinoma (Kurman 1985). The latest World Health Organization
(WHO) classification for endometrial hyperplasia now differen-
tiates only two categories of endometrial hyperplasia: hyperplasia
without atypia and atypical hyperplasia/endometrioid intraepithe-
lial neoplasia (Zaino 2014). Progression rates have been reported
as less than 5% for non-atypical hyperplasia but 28% for atypical
hyperplasia cumulatively over 20 years. This difference in progres-
sion risk has been seen at interval-specific time points of four years,
nine years, and 20 years post diagnosis (Lacey 2010). Risk factors
for endometrial hyperplasia are, predictably, very similar to those
for endometrial carcinoma and include obesity, diabetes mellitus,
nulliparity, tamoxifen use, oestrogen therapy, and polycystic ovary
syndrome (PCOS) (Torres 2012).
Polycystic ovary syndrome is a metabolically driven gynaecolog-
ical disorder that is thought to affect 10% of women of child-
bearing age (Chang 2002). A diagnosis of PCOS must fulfil the
widely accepted Rotterdam criteria for two or more of the follow-
ing in the absence of another cause of chronic anovulation: hyper-
androgenism (clinical or biochemical), chronic oligo/anovulation,
and polycystic ovaries apparent on ultrasound (ESHRE/ASRM
2004). Prevalence of endometrial hyperplasia in women with
PCOSvaries greatly in the literature - between5%and10%(Holm
2012; Rudnicka 2009) - but risk of endometrial carcinoma is well
founded, as women with PCOS possess a three-fold increased risk
of developing endometrial carcinoma when compared with the
non-PCOS population (Haoula 2012).
The aim of endometrial hyperplasia treatment, whether or not
PCOS is a comorbidity, is to control abnormal vaginal bleed-
ing while minimising risk of progression to endometrial carci-
noma. Historically, endometrial hyperplasia without atypia has
been treated medically with oral progestogens (alone or in com-
bination with oestrogen in PCOS) or intrauterine progestogens,
inhibiting oestrogen-driven cell growth and inducing withdrawal
bleeds (Yang 2011). This treatment provides the benefit of pre-
serving fertility but is associated with side effects - in the short
term, headaches, mood changes, and acne or breast tenderness,
and over the longer term, risk of a thromboembolic event or breast
cancer (BNF 2017). The side effects of these medications has had
the effect of potentially hindering compliance, consequently pro-
ducing a relatively high relapse rate. In one study, 30.3% and
13.7% of women treated with oral progestogens and intrauter-
ine levonorgestrel, respectively, had relapse of their endometrial
hyperplasia (Gallos 2013). However, longer-term side effects of
progestogens can be mitigated by educating women about the
symptoms of thromboembolic events and by ensuring that they
attend regular breast cancer screening programmes. For women
with atypia and for those who are resistant to progestogens, surgi-
cal hysterectomy is the treatment of choice (Shafiee 2014).
Description of the intervention
Metformin, a biguanide that acts as an insulin sensitiser, is the
oral hypoglycaemic agent most commonly used for treatment of
type 2 diabetes mellitus. It acts to inhibit hepatic gluconeogenesis,
decreasing liver glucose production and thereby reducing levels of
circulating glucose and insulin.
Metformin is also prescribed for women with PCOS to induce
weight loss and improve menstrual regularity, both as monother-
apy and in combination with a progestogen. It is frequently
used to treat ovulatory dysfunction in women with PCOS who
have shown resistance to treatment with clomiphene. Despite
widespread use of metformin in women with PCOS, a system-
atic review comparing metformin with the oral contraceptive pill
found no definitive improvement in clinical or biochemical fea-
tures (Costello 2007). Metformin has an established side effect
profile that includes nausea and vomiting, diarrhoea, abdominal
pain, and changes in taste, as well as rarer or less-publicised ef-
fects such as lactic acidosis or decreased B12 absorption, possibly
leading to anaemia and potentially irreversible neuronal damage if
left unmonitored and uncorrected for prolonged periods (de Jager
2010).
How the intervention might work
Hyperinsulinaemia secondary to insulin resistance is thought to
exhibit a mitogenic effect, inducing cell division via mitosis - a risk
factor for hyperplasia - and, ultimately, carcinoma development.
This effect is likely due to its activity at the insulin-like growth fac-
tor-1 receptor, promoting proliferation and angiogenesis, which
can be demonstrated by the positive correlation between diabetes
and breast and gynaecological cancers (Vrachnis 2016). Insulin-
mediating effects of metformin, then, show evidence of reduc-
ing incidence and improving survival among these malignancies,
although the evidence is mixed (Chlebowski 2012; Nevadunsky
2014). The link between insulin resistance and cell proliferation
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offers an intriguing potential therapeutic target for reversing hy-
perplasia and preventing endometrial carcinoma. Some early trials
have corroborated this link, showing effectiveness of metformin
in inducing endometrial atrophy in benign endometrial prolifer-
ative disorders; one reported atrophy and therefore reversal of en-
dometrial hyperplasia in 96% of women treated with metformin
(Tabrizi 2014).
Other proposed mechanisms of the anticancer properties of met-
formin include its direct effects on cell signalling pathways, includ-
ing inhibition of the mammalian target of rapamycin (mTOR)
and inhibition of mitogen-activated protein kinase (MAPK) and
Akt activity. These pathways are involved in cell proliferation and
therefore play a key role in both hyperplasia and cancerous lesions
in any tissue. As metformin inhibits these pathways, cell prolif-
eration will be hindered, reducing the chance of development of
cancerous lesions (Alimova 2009; Ben 2011).
Why it is important to do this review
Medical therapy for endometrial hyperplasia currently involves
multiple side effects and continued risk of recurrence. Therefore, a
systematic review of a novel, alternative therapy is needed to collate
the evidence to date and to guide future clinical trials. Risk of pro-
gression from endometrial hyperplasia to carcinoma is significant;
up to 28% of women with endometrial hyperplasia with atypia go
on to develop carcinoma - the most common fatal gynaecological
malignancy (Lacey 2010). This rate is expected to increase glob-
ally by up to 100% over the next 20 years (Dowling 2011). The
biguanide insulin sensitiser metformin has been linked to reversal
of endometrial hyperplasia and, if it can be used in this way, may
contribute to decreasing the prevalence of endometrial carcinoma
without use of hormonal contraceptives or irreversible infertility
following a hysterectomy (Tabrizi 2014). Although publications
include in vitro studies reporting reversed endometrial hyperpla-
sia in mice and cell lines, as well as some case reports, results of
treatment are relatively ambiguous, and the mode of action, ef-
fectiveness, and safety of metformin remain unclear (Erdemoglu
2009; Legro 2007; Rosato 2011; Session 2003; Shen 2008). This
review may help to clarify the role of metformin in the treatment
of women with this disease.
O B J E C T I V E S
To determine the effectiveness and safety of metformin in treating
women with endometrial hyperplasia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), both pub-
lished and unpublished. We also included cross-over trials, but we
planned to use in the analysis only data from the first phase of
these trials.
Types of participants
We included women with histologically confirmed endometrial
hyperplasia of any type.
Types of interventions
We included trials comparing metformin with placebo or no treat-
ment, conventionalmedical treatment (typically progestogens, e.g.
oral or intrauterine), or any other active intervention. We also in-
cluded trials that provided co-interventions (e.g. metformin plus
progesterone vs progesterone), but we planned to analyse results
of these studies separately.
Types of outcome measures
Primary outcomes
1. Regression of endometrial hyperplasia histology (with or with-
out atypia) towards normal histology
Secondary outcomes
2. Recurrence of endometrial hyperplasia
3. Progression of endometrial hyperplasia to endometrial cancer
4. Hysterectomy rate
5. Abnormal uterine bleeding
6. Health-related quality of life, as reported in the included studies
7. Adverse effects during treatment, as reported in the included
studies
Search methods for identification of studies
We searched for all published and unpublished RCTs of met-
formin for endometrial hyperplasia without language restriction.
Review authors liaised with the Cochrane Gynaecology and Fertil-
ity Group Trials Search Co-ordinator and Information Specialist
when conducting the search.
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Electronic searches
In accordance with guidance from the Cochrane Gynaecology
and Fertility Group, we created search strategies for the following
electronic databases to identify all relevant RCTs. We searched the
following databases from date of inception to 10 January 2017.
1. Cochrane Gynaecology and Fertility Specialised Register
(Procite platform; inception to 10 January 2017) (Appendix 1).
2. Cochrane Central Register of Studies Online (CRSO)
(Web platform; searched 10 January 2017) (Appendix 2).
3. Ovid MEDLINE (Ovid platform;1946 to 10 January
2017) (Appendix 3).
4. Ovid Embase (Ovid platform; 1980 to 10 January 2017)
(Appendix 4).
5. EBSCO Cumulative Index to Nursing and Allied Health
Literature (CINAHL) (Ebsco platform;1961 to 10 January
2017) (Appendix 5).
6. PubMed (Web platform; searched 10 January 2017)
(Appendix 6).
7. Google Scholar (Web platform; searched 10 January 2017)
(Appendix 7).
We also searched the following trials registers and databases to
identify ongoing and unpublished trials.
1. ClinicalTrials.gov (Web platform; searched 10 January
2017) (Appendix 8).
2. World Health Organization International Trials Registry
Platform search portal (Web platform; searched 10 January
2017) (Appendix 9).
3. OpenGrey (Web platform; searched 10 January 2017)
(Appendix 10).
4. Latin American Caribbean Health Sciences Literature
(LILACS) (Web platform; searched 10 January 2017) (Appendix
11).
We have presented a list of search strategies in the appendices. For
unpublished trials, we emailed the contact person to obtain further
information to aid our assessment as to whether they should be
included.
Searching other resources
We handsearched the bibliographies of all included studies and
reviews on this topic. We also handsearched conference abstracts
of the European Society of Human Reproduction and Embryol-
ogy (ESHRE) 2015 and the American Society for Reproductive
Medicine (ASRM) 2015, as these were not included inCENTRAL
at the time of the search. Previous abstracts from these conferences
had been incorporated into the Cochrane Gynaecology and Fer-
tility Specialised Register.
Data collection and analysis
Selection of studies
We uploaded the titles and abstracts of all studies retrieved by elec-
tronic searches to a reference manager programme (Covidence)
and removed duplicates. Two review authors (two of NC, TO, JS,
HS) independently assessed titles and abstracts to identify studies
for potential inclusion in the review.We sought full-text reports for
potentially relevant studies. Two review authors (two of NC, TO,
JS, HS) then independently assessed each full-text report against
the inclusion criteria and documented a justification for exclu-
sion of each study. Review authors resolved disagreements between
them regarding trial suitability by discussion or by consultation
with a third review author. We screened studies for duplicate pub-
lication by comparing study author names and study locations,
dates, and durations. When uncertainty about study methods or
the possibility of duplicate studies arose, we contacted the authors
of relevant papers. We constructed a flow chart (Figure 1) to illus-
trate selection of studies for inclusion in this review according to
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines (Moher 2009).
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Figure 1. Flow diagram.
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Data extraction and management
Two review authors independently extracted data using a data
extraction formbased on the ’Checklist of items to consider in data
collection or data extraction’ provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). If, during
study selection, we found a study that had been publishedmultiple
times, we planned to extract and collate study data into a single
file. We treated such studies as a single unit of interest for the
review and attributed multiple references to the single file. When
necessary, we contacted study authors to request additional data
on their methods and/or results.
Assessment of risk of bias in included studies
Two review authors (two of NC, TO, HS, JS) independently as-
sessed each included study for risk of bias using theCochrane ’Risk
of bias’ assessment tool, as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We assessed
bias according to the following domains.
1. Selection bias (random sequence generation and allocation
concealment).
2. Performance bias (blinding of participants and personnel).
3. Detection bias (blinding of outcome assessments).
4. Attrition bias (incomplete outcome data).
5. Reporting bias (selective reporting).
6. Other bias (other sources of bias).
We graded risk of bias as ’low’, ’high’, or ’unclear’ for all domains
mentioned above by using the ’Criteria for judging risk of bias’
in the ‘Risk of bias’ assessment tool (Higgins 2011). We resolved
disagreements by discussion and, when necessary, by consultation
with a third review author. We have provided a justification for
each judgement in the ’Risk of bias’ table and, when possible, a
quote from the study to support this judgement. We considered
our risk of bias assessmentwhen interpreting findings of the review,
for example, whenperforming the sensitivity analysis. Tominimise
bias in selective reporting of trial outcomes, we planned, when
possible, to compare published protocols against methods and
outcomes described in the final report.
Measures of treatment effect
For survival outcomes (e.g. regression of endometrial hyperplasia,
recurrence of endometrial hyperplasia, progression to endometrial
carcinoma), we planned to calculate hazard ratios if data were
available. Otherwise, we would calculate rates at a set time point,
using the Mantel-Haenszel odds ratio (OR) and the numbers of
events in control and intervention groups.
For continuous data, we planned to use means, standard devia-
tions, and mean differences (MDs). We planned to treat ordinal
data, such as side effect severity scoring systems and health-related
quality of life questionnaires, as continuous data for purposes of
analysis. If different scales were used to report similar outcomes
(e.g. change in endometrial thickness), we planned to calculate the
standardised mean difference (SMD). We planned to express the
SMD effect as small (0.2 to < 0.5), medium (0.5 to < 0.8), or large
(≥ 0.8) (Cohen 1988), and to provide 95% confidence intervals
(CIs) for all outcomes.
We planned to report dichotomous and continuous outcomes
measured after short-term treatment (up to six months post treat-
ment), medium-term treatment (6 to 12 months post treatment),
and long-term treatment (more than 12 months post treatment).
Unit of analysis issues
We performed the primary analysis per woman. If a valid analysis
was not possible, we planned to briefly summarise the data but
not include them in the meta-analysis. We planned to include in
the analysis only first-phase data from cross-over trials.
Dealing with missing data
Weanalysed the data on an intention-to-treat basis as far as possible
and attempted to obtain missing data from the original trialists.
When contacting study authors for missing information, we sent
a first reminder email 14 days and a second reminder email 21
days after the initial email. When data could not be obtained,
we analysed only available data. We have discussed the potential
impact of missing data in the Discussion section of the review.
Assessment of heterogeneity
Weplanned to consider whether clinical andmethodological char-
acteristics of included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. We assessed
statistical heterogeneity using the measure of I². We considered an
I² greater than 50% to indicate substantial heterogeneity (Higgins
2003; Higgins 2011).
Assessment of reporting biases
Reporting bias is a potential issue for all reviews. We aimed to
identify and minimise reporting bias in our analysis by creating
a comprehensive search strategy and utilising a multitude of elec-
tronic databases, including those that record unpublished work
and work prepared in languages other than English. This ensured
that we maximised the yield of eligible studies included in the re-
view and were able to identify cases of data duplication.
We planned that if we included 10 or more studies in a single anal-
ysis, we would use a funnel plot to explore the possibility of small-
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study effects (i.e. the tendency for estimates of the intervention
effect to be more beneficial in smaller studies).
Data synthesis
If identified studies were sufficiently similar, we aimed to combine
the data In Review Manager software (RevMan 2014) using a
fixed-effect model for the following comparisons.
1. Metformin versus placebo or no treatment.
2. Metformin versus progestogens.
3. Metformin versus other active intervention.
4. Metformin plus co-intervention versus co-intervention
alone.
We aimed to stratify analyses by dose of metformin (high, moder-
ate, low). We have graphically displayed the results of these meta-
analyses, with increasing odds (regardless of whether the outcome
is beneficial) demonstrated by a marker right of the centre-line,
and decreasing odds by a marker left of the centre-line.
Subgroup analysis and investigation of heterogeneity
When data were available, we aimed to conduct subgroup analyses
to obtain separate evidence for the following subgroups.
1. Women with PCOS.
2. Women with atypical endometrial hyperplasia.
If pooled data demonstrate substantial heterogeneity (> 50%), we
planned to consider additional subgroup analyses (e.g. by dose or
route of metformin) and/or sensitivity analyses. We planned to
acknowledge the degree of heterogeneity when interpreting the
meta-analysis.
Sensitivity analysis
We aimed to conduct a sensitivity analysis for the primary out-
come to determine whether conclusions are robust to our choice
of methods with regards to study eligibility and analysis. Through
this sensitivity analysis, we planned to explore whether review con-
clusions would have been different if:
1. all studies with high risk of bias in one or more domains
were excluded from the analysis;
2. a random-effects model had been implemented; or
3. the effect estimate had been expressed as risk ratio (RR)
rather than OR.
Overall quality of the body of evidence: ’Summary of
findings’ tables
Two review authors working independently prepared ’Summary
of findings’ tables by using GRADEpro Guideline Development
Tool software (GRADEpro GDT 2015) and Cochrane methods
(Higgins 2011). In this table, we have presented a concise overview
of the quality of available evidence for the main comparison (met-
formin vs megestrol acetate) and for an additional comparison
(metformin plus megestrol acetate vs megestrol acetate alone) per-
taining to all review outcomes (regression of endometrial hyper-
plasia towards normal histology, recurrence of endometrial hyper-
plasia, progression of endometrial hyperplasia to endometrial can-
cer, hysterectomy rate, abnormal uterine bleeding, health-related
quality of life as reported in included studies, and adverse effects
during treatment as reported in included studies). In accordance
with GRADE (Grades of Recommendation, Assessment, Devel-
opment and Evaluation Working Group) criteria (study limita-
tions, consistency of effect, imprecision, indirectness, and publi-
cation bias), two review authors independently rated the quality
of the evidence as ’high’, ’moderate’, ’low’, or ’very low’. We have
documented the justification for each grade awarded and have in-
corporated the overall grade into our final conclusions.
R E S U L T S
Description of studies
Results of the search
Through the search, we retrieved 217 records; we excluded 195 on
the basis of title and abstract review. We sought the full text of the
remaining 22 articles and found that eight met our inclusion crite-
ria.We excluded 14 articles. Of the eight full-text articles reviewed,
five report findings of three completed studies, and three de-
scribe ongoing studies. See study tables Characteristics of included
studies, Characteristics of excluded studies, and Characteristics of
ongoing studies and the PRISMA flow chart in Figure 1.
Included studies
We included in this review three RCTs, which are described in five
articles; three articles describe one study.
Study design and setting
All three included studies were single-centre studies based in hos-
pital outpatient clinics in China or Iran (Shan 2014; Sharifzadeh
2016; Tabrizi 2014).
Participants
In total, investigators randomised 110 women with endometrial
hyperplasia across the three RCTs. Critically, histopathological di-
agnoses reported by each study differed.One included all endome-
trial hyperplasia, with or without atypia (Tabrizi 2014). One re-
ported only hyperplasia with atypia (Shan 2014). The third de-
scribed hyperplasia without atypia (Sharifzadeh 2016). Tabrizi in-
cluded in the randomisation participants with endometrioid en-
dometrial carcinoma and disordered proliferative endometrium,
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which we excluded from our analysis in this review (Tabrizi 2014).
Shan restricted participants to those under 45 years of age (Shan
2014). The other two studies applied no age restriction.
Interventions
Two studies compared metformin against megestrol acetate (
Sharifzadeh 2016; Tabrizi 2014). The other included study exam-
ined metformin and megestrol acetate dual therapy against mege-
strol acetate monotherapy (Shan 2014).
Outcomes
Two studies measured outcomes at 12 weeks (Shan 2014;
Sharifzadeh 2016). One measured outcomes at three months
(Tabrizi 2014). Thus for all eligible studies, analysis could be per-
formed only on “short-term treatment” outcomes. All studies re-
ported on the review’s primary outcome - regression of endome-
trial hyperplasia towards normal histology. Additionally, study au-
thors reported on progression of endometrial hyperplasia to en-
dometrial cancer, when it occurred.
Excluded studies
We excluded 14 full-text reports for the following reasons.
1. Eight were not RCTs.
2. Three did not include women with endometrial
hyperplasia.
3. Three did not measure outcomes histologically.
Ongoing studies
We identified three ongoing studies, two of which are due to be
completed in 2017 (we contacted study authors throughout the
review process to request preliminary results) and one in 2019.
Risk of bias in included studies
We have shown risk of bias as judged by review authors for all
domains in Figure 2 and have summarised this information in
Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
We judged that one study was at low risk of bias related to se-
quence generation, as researchers used a computer to generate a
randomised table (Shan 2014).We determined that the remaining
two studies were at unclear risk of this bias, as trialists did not
describe the method used (Sharifzadeh 2016; Tabrizi 2014).
Allocation concealment
We thought that one study was at low risk of allocation con-
cealment bias, as investigators used sealed envelopes (Sharifzadeh
2016).We determined that two studies were at unclear risk of bias,
as study authors did not describe the method used (Shan 2014;
Tabrizi 2014).
Blinding
We considered under our primary outcome that lack of blinding
may influence symptom reporting by both investigators and pa-
tients but not histological results. Therefore, two studies in which
neither patients nor investigators were blinded had high risk of
bias for this domain (Shan 2014; Sharifzadeh 2016). One study
did report blinding of data analysers (Shan 2014). The remaining
study described no blinding process, and we therefore judged this
trial to be at unclear risk of bias for this domain (Tabrizi 2014).
Incomplete outcome data
Two studies were at low risk related to attrition bias. One of these
studies reported that no participants of 43 were lost from the study
(Tabrizi 2014). The other reported that only three participants
of 45 were lost: One was lost to follow-up and two discontinued
the intervention (Sharifzadeh 2016). We judged the remaining
study to be at high risk of bias in this domain, as only 16 of 30
participants completed 12 weeks of therapy and were included in
the analysis (Shan 2014).
Selective reporting
We judged all three studies to be at unclear risk of reporting bias
owing to lack of publication of protocols before studies were pub-
lished (Shan 2014; Sharifzadeh 2016; Tabrizi 2014). Two studies
excluded participants “lost to follow-up” from any analysis, but it
remains unclear whether available case analysis had been planned
within their protocols (Shan 2014; Sharifzadeh 2016).
All three studies reported all outcomes appropriately.
Other potential sources of bias
We judged that one study had potential sampling bias, as partici-
pants were not matched between intervention and control groups
by histology, age, features of metabolic syndrome, or PCOS diag-
nosis, and therefore investigators did not control for these known
risk factors for development of endometrial hyperplasia (Tabrizi
2014). This study also had potential exclusion bias as, although
diagnosis of diabetes was an exclusion criterion, some pre-inter-
vention blood glucose values appear to show some undiagnosed
cases of diabetes but were still included, showing inconsistent ex-
clusion of diabetic patients - again a known effector of endometrial
histology.
We identified no potential sources of within-study bias in the
remaining two studies.
Effects of interventions
See: Summary of findings for the main comparisonMetformin
compared with megestrol acetate for endometrial hyperplasia;
Summary of findings 2 Metformin plus megestrol acetate
compared with megestrol acetate for endometrial hyperplasia
1. Metformin versus megestrol acetate
We included two studies in this comparison.
Primary outcome
1.1 Regression of endometrial hyperplasia histology (with or
without atypia) towards normal histology
Evidence was insufficient to showwhether there was any difference
in rates of regression of endometrial hyperplasia histology towards
normal histology when metformin was compared with megestrol
acetate (odds ratio (OR) 3.34, 95% confidence interval (CI) 0.97
to 11.57, two RCTs, n = 59, I² = 0%, very low-quality evidence;
Analysis 1.1). Although one study reported the presence or ab-
sence of atypia, data were insufficient to track these participants
from initial to final histological results; therefore, we performed
no subgroup analysis (Tabrizi 2014).
Secondary outcomes
1.2 Progression of endometrial hyperplasia to endometrial
cancer
Two studies provided data for this outcome (n = 59) but reported
no events in either arm (Analysis 1.2).
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1.3 Hysterectomy rate
It is uncertain whether metformin and megestrol acetate are dif-
ferent in terms of hysterectomy rates (OR 0.91, 95% CI 0.05 to
15.52, two RCTs, n = 61, very low-quality evidence; Analysis 1.3).
1.4 Abnormal uterine bleeding
It is unresolved whether metformin and megestrol acetate showed
a difference in rates of abnormal uterine bleeding (OR 0.91, 95%
CI 0.05 to 15.52, two RCTs, n = 44, very low-quality evidence;
Analysis 1.4). The only study contributing data to this analysis
reported only two events.
Other secondary outcomes
Study authors provided no data on recurrence of endometrial hy-
perplasia, health-related quality of life, or adverse events, with the
exception of abnormal uterine bleeding, as described above.
2. Metformin plus megestrol acetate versus
megestrol acetate alone
We included only one study in this comparison.
Primary outcome
2.1 Regression of endometrial hyperplasia histology (with or
without atypia) towards normal histology
Whether metformin plus megestrol acetate and megestrol acetate
alone are different in terms of rates of regression of endometrial
hyperplasia histology towards normal histology remains uncertain
(OR 9.00, 95% CI 0.94 to 86.52, one RCT, n = 16, very low-
quality evidence; Analysis 2.1). The single study included in this
analysis recorded only eight events.
Secondary outcomes
2.2 Recurrence of endometrial hyperplasia
Whether metformin plus megestrol acetate and megestrol acetate
alone are different in terms of rates of recurrence of endometrial
hyperplasia among women who achieve regression remains unre-
solved (OR not estimable, 95% CI not estimable, one RCT, n =
8, very low-quality evidence; Analysis 2.2). The single study in-
cluded in this analysis recorded no events.
2.3 Progression of endometrial hyperplasia to endometrial
cancer
Whether metformin plus megestrol acetate and megestrol acetate
alone are different in terms of rates of progression of endometrial
hyperplasia to endometrial cancer remains uncertain (OR not es-
timable, 95% CI not estimable, one RCT, n = 16, I² = not appli-
cable, very low-quality evidence; Analysis 2.3). The single study
included in this analysis recorded no events.
2.4 Hysterectomy rate
Whether metformin plus megestrol acetate and megestrol acetate
alone are different in terms of hysterectomy rates in women with
endometrial hyperplasia remains unresolved (OR 0.29, 95% CI
0.01 to 8.37, one RCT, n = 16, I² = not applicable, very low-
quality evidence; Analysis 2.4). The single study included in this
analysis recorded only two events: one in the intervention arm and
one in the study control arm.
2.5 Adverse effects during treatment
Three of eight women (37.5%) in the metformin plus megestrol
acetate study arm reported nausea; however, this was resolved
without further treatment (Analysis 2.5). Investigators recorded
additional adverse effects during the follow-up period, including
thrombosis, lactic acidosis, abnormal liver and renal function, and
other toxicities and complaints, but whether these were merely in-
quired about or occurred within participant populations remains
unclear.
Other secondary outcomes
Study authors provided no data on abnormal uterine bleeding or
health-related quality of life.
Other analyses
Data were insufficient for performance of subgroup analyses.
Sensitivity analysis by risk of bias was not appropriate because we
judged all included studies to have high risk of bias. Sensitivity
analyses by effect estimate and choice of statistical model did not
substantially change the main findings of this review.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Metformin plus megestrol acetate compared with megestrol acetate for endometrial hyperplasia
Patient or population: women with endometrial hyperplasia
Setting: hospital outpat ient clinic
Intervention: metform in plus megestrol acetate
Comparison: megestrol acetate
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk withmegestrol ac-
etate
Risk with metformin
plus megestrol acetate
Regression of endome-
trial hyperplasia (with
or without atypia) to-
wards normal histology
Assessed by histologi-
cal examinat ion
Follow-up: 3 months
250 per 1000 750 per 1000
(239 to 966)
OR 9.00
(0.94 to 86.52)
16
(1 RCT)
⊕©©©
VERY LOWa,b
Normal histology is de-
f ined as prolif erat ive or
secretory endometrium
Recurrence of endome-
trial hyperplasia
Follow-up: median 10.5
months
0 per 1000 0 per 1000
(0 to 0)
Not est imable 8
(1 RCT)
⊕©©©
VERY LOWa,c
Measured in the sub-
set of women who
achieved regression
Progression of en-
dometrial hyperplasia
to endometrial cancer
Follow-up: median 10
months
0 per 1000 0 per 1000
(0 to 0)
Not est imable 16
(1 RCT)
⊕©©©
VERY LOWa,c
Hysterectomy rate 125 per 1000 40 per 1000
(1 to 545)
OR 0.29
(0.01 to 8.37)
16
(1 RCT)
⊕©©©
VERY LOWa,b
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Abnormal uterine
bleeding
See comment Not est imable (0 studies) - No data for abnormal
uterine bleeding for this
comparison
Health-related quality
of lif e (HRQL)
See comment Not est imable (0 studies) - No data for HRQL for
this comparison
Adverse ef fects during
treatment
Assessed self -report
3/ 8 (37.5%) of part icipants who took metform in
had nausea that sett led without further treat-
ment. Adverse ef fects, including ‘‘thrombosis,
lact ic acidosis, abnormal liver and renal funct ion,
and other toxicit ies or complaints’’ were recorded
- (1 RCT) ⊕©©©
VERY LOWa,b
*The risk in the intervention group (and its 95%conf idence interval) is based on mean risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io.
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded two levels for very serious risk of bias: The included study provided inadequate detail regarding study design,
which was insuf f icient ly clarif ied when study authors were approached. The random sequence generat ion was altered, and
the allocat ion concealment was unclear. This was an open-label study with attrit ion of 6 of the original 22 randomised
part icipants during the period of the study who were not evaluated by an intent ion-to-treat analysis. For the outcome of
regression, only a subset of women were included in the analysis.
bDowngraded by two levels for very serious imprecision: Very low event rate and/ or conf idence intervals are compatible with
a large ef fect in one or both groups, or with null ef fect.
cDowngraded by two levels for very serious imprecision: Sample size was t iny, follow-up was short , and no events were
reported.
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D I S C U S S I O N
Summary of main results
Two of the three studies included in this review compared met-
formin against megestrol acetate, and one study compared met-
formin and megestrol acetate dual therapy against megestrol ac-
etate monotherapy.
Trial results provided no evidence to support or refute short-term
use of metformin either alone or in combination with megestrol
acetate for treatment of endometrial hyperplasia versus megestrol
acetate alone. Whether these treatments are different in terms of
rates of hysterectomy, abnormal uterine bleeding, alteration in en-
dometrial histology, or rates of progression to endometrial cancer
remains uncertain. The quality of the evidence is very low.
Overall completeness and applicability of
evidence
We undertook a comprehensive search of a range of databases and
trials registries with no language restrictions to identify published,
unpublished, and ongoing studies. Thus we are confident that we
have identified all potentially relevant randomised controlled trials
(RCTs). However, we identified for inclusion in this review only
three studies conducted in only two countries; all had small sam-
ple sizes, and consequently overall applicability remains unclear.
Completeness of evidence was limited by lack of subgroup data
(whether effects were the same in individuals both with and with-
out atypia) and by the relatively short-term follow-up explored
(12 weeks or 3 months in all three studies).
Quality of the evidence
Using GRADE, review authors determined that the evidence was
of very low quality both for the main comparison of metformin
versus megestrol acetate and for the additional comparison of met-
formin plus megestrol acetate versus megestrol acetate alone. For
both comparisons, we downgraded the quality of evidence owing
to very serious risk of bias (associated with poor reporting, attri-
tion, and limitations in study design) and imprecision as major
factors. All studies had very small sample sizes, especially when
assessing relatively rare events such as progression of endometrial
hyperplasia to endometrial cancer. Confidence intervals were com-
patible with a large effect in one or both groups, or with a null
effect.
Potential biases in the review process
We conducted this review according to guidelines presented in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). Two review authors independently performed each step of
the review process, thus reducing potential bias when subjective
decisions were required. When the two review authors disagreed,
we sought the opinions of a third review author. Furthermore, this
review has undergone peer review; thus we are confident that the
findings reported here are a true representation of current evidence
pertaining to this question.
Investigators excluded from the study’s final analysis 6 of the 22
randomised participants (Shan 2014). Study authors provided no
details of participants excluded owing to incomplete data, nor did
they provide data previously collected for these participants. Study
authors provided no data on participants who dropped out. This
was reflected in our rating of attrition bias for the study.
We note that standard therapy doses for metformin and megestrol
acetate and megestrol acetate in combination with metformin dif-
fered, and we recognise the impact this may have had on the ther-
apeutic response. However, we did not directly compare in this
review studies in which these doses differed but included them in
two separate comparisons.
We made the decision to include one study even though the
authors of this study performed only subgroup analysis (Tabrizi
2014). We made this decision because the subgroup analysis was
relevant to the study, and further evidence available in the litera-
ture was limited.
Agreements and disagreements with other
studies or reviews
To our knowledge, no systematic review has compared the effects
of metformin versusmegestrol acetate nor the effects ofmetformin
plus megestrol acetate versus megestrol acetate alone.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Review authors found insufficient evidence to support or refute
the use of metformin given alone or in combination with standard
therapy, specifically megestrol acetate, for treatment of women
with endometrial hyperplasia.
Implications for research
Well-designed randomised controlled clinical trials are required to
investigate the effectiveness and safety of metformin for treating
women with endometrial hyperplasia in comparison with other
interventions, including oral or intrauterine progestogens. These
trials should provide long-term follow-up of womenwith endome-
trial hyperplasia (both with and without atypia) in all arms of
the trial, including assessment of progression to endometrial car-
cinoma and assessment of quality of life.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Shan 2014
Methods Randomised controlled trial
22 randomised participants, 16 included in the analysis
Timing: August 2012 to January 2013
Setting: hospital outpatient clinic, in China
Participants Women given a pathological diagnosis of endometrial atypical hyperplasia
Aged 45 years or less
Participants expressed a desire to preserve fertility.
Interventions Metformin plus megestrol acetate (n = 8): received 500 mg of oral metformin 3 times a
day and 160 mg of oral megestrol acetate daily
Megestrol acetate (n = 8): received 160 mg of oral megestrol acetate daily
Both groups: 12 weeks of therapy
Outcomes Regression of endometrial hyperplasia histology (with or without atypia) towards normal
histology; Recurrence of endometrial hyperplasia among women who had regression;
Progression of endometrial hyperplasia to endometrial cancer; Hysterectomy rate; Ad-
verse effects during treatment, as reported in the included studies
Notes Of 6 not included in the analysis, 3 participants were lost to follow-up and 3 had
incomplete data, leaving 8 participants in each group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Communication with authors: “Using
computer, we got a randomized table with
a total sample of 16. Actually, we used func-
tion ”RAND“ in excel to form the table
and changed these randomized numbers to
0 or 1. When a subject was enrolled, she
would get a number. 0meansMA only and
1 means MA + metformin.”
Allocation concealment (selection bias) Unclear risk Communication with authors: “Using
computer, we got a randomized table with
a total sample of 16. Actually, we used func-
tion ”RAND“ in excel to form the table
and changed these randomized numbers to
0 or 1. When a subject was enrolled, she
would get a number. 0meansMA only and
1 means MA + metformin.”
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Shan 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Communication with authors: “This study
was an open label study. However, when
[analyzing] the data, the analyzer kept un-
known of the certain meaning of number
0 or 1. And only investigator or sponsor
had the right of access to personal data of
subjects.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Communication with authors: “This study
was an open label study. However, when
[analyzing] the data, the analyzer kept un-
known of the certain meaning of number
0 or 1.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 30 participants, 16 completed 12
weeks of therapy. 8 women chose to un-
dergo an operation and were excluded be-
fore randomisation, 3 were lost during fol-
low-up, and 3 had incomplete data and
were excluded from the end analysis (no
blood test results available). It is unclear
why the absence of blood test data meant
that participants were omitted from histo-
logical assessment
Selective reporting (reporting bias) Unclear risk No protocol was published before publi-
cation of the study. Outcomes have been
appropriately reported. 3 participants died
following completion of the study andwere
not included in the analysis, but it is unclear
whether available case analysis had been
planned
Other bias Low risk No suggestion of other sources of bias
Sharifzadeh 2016
Methods Randomised controlled trial
45 randomised participants, 42 included in the analysis
Timing: February to May 2016
Setting: hospital outpatient clinic, in Iran
Participants Women with histopathologically confirmed simple endometrial hyperplasia without
atypia
Interventions Metformin (n = 22): received 500 mg oral metformin twice daily for 4 weeks, then 500
mg 3 times a day for a further 8 weeks
Megestrol acetate (n = 20): 40 mg oral megestrol acetate daily for 12 weeks
25Metformin for endometrial hyperplasia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sharifzadeh 2016 (Continued)
Both groups: 12 weeks of therapy
Outcomes Regression of endometrial hyperplasia histology (with or without atypia) towards normal
histology
Notes 1 participant were lost to follow-up and 2 discontinued treatment, both in the megestrol
acetate arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Communication with authors: “Random-
ization was performed using sealed, se-
quentially distributed envelopes to which
the letters A and B had been allocated: the
letter A to the metformin group and the
letter B to the megestrol group. The pa-
tients chose one of the envelopes which
were opened by the investigator’s colleague
and, based on the letters, the groups of pa-
tients were determined.”
Allocation concealment (selection bias) Low risk Communication with authors: “Random-
ization was performed using sealed, se-
quentially distributed envelopes to which
the letters A and B had been allocated: the
letter A to the metformin group and the
letter B to the megestrol group. The pa-
tients chose one of the envelopes which
were opened by the investigator’s colleague
and, based on the letters, the groups of pa-
tients were determined.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Communication from trial authors: “The
investigators and patients were not blind to
interventions.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Communication from trial authors: “The
investigators and patients were not blind to
interventions.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant was lost to follow-up and 2
discontinued intervention
Selective reporting (reporting bias) Unclear risk Protocol was not published. 1 participant
was lost to follow-up and 2 discontinued
intervention. These participants were ex-
cluded from the analysis, but it is unclear
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Sharifzadeh 2016 (Continued)
whether available case analysis had been
planned
Other bias Low risk No suggestion of other sources of bias
Tabrizi 2014
Methods Randomised controlled trial (subgroup analysis for the purposes of this review; see below)
43 randomised participants, all 43 analysed by study authors
Review authors excluded 26 participants as they had a histological diagnosis of “Disor-
dered proliferative endometrium” or “Endometrioid endometrial carcinoma” at baseline,
leaving 17 participants for analysis
Timing: May to August 2013
Setting: hospital outpatient clinic, in Iran
Participants Study authors state that they included participants with abnormal uterine bleeding and
a histological diagnosis of disordered endometrial proliferation or simple hyperplasia;
however, the randomised participant cohort also includes individuals with endometrial
carcinoma and complex hyperplasia, with and without atypia
Interventions Metformin (n = 11): received oral metformin 500 mg daily in the first to fourth week,
then 500 mg twice daily from the fourth week onwards
Megestrol acetate (n = 6): received oral megestrol acetate 40 mg daily
Both groups: 3 months of therapy
Outcomes Regression of endometrial hyperplasia histology (with or without atypia) towards normal
histology; Progression of endometrial hyperplasia to endometrial cancer
Notes We contacted study authors to request more information on random sequence gener-
ation, allocation concealment, and blinding processes for participants, personnel, and
outcomes. They provided no relevant information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information withinmethod re-
garding assessing risk of bias, even after
study authors were contacted
Allocation concealment (selection bias) Unclear risk Insufficient information withinmethod re-
garding assessing risk of bias, even after
study authors were contacted
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information withinmethod re-
garding assessing risk of bias, even after
study authors were contacted
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Tabrizi 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information withinmethod re-
garding assessing risk of bias, even after
study authors were contacted
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcome data incomplete for participants
included in this review relative to the whole
cohort randomised
Selective reporting (reporting bias) Unclear risk Noprotocol was published before the study
report was published, so it is difficult to es-
tablish whether selective outcome report-
ing occurred
No adverse effects were reported.
Other bias High risk 1. Potential sampling bias: intervention and
control groups not matched by histology,
age, features of metabolic syndrome, or
PCOS. Study reports inclusion criteria to
be histology of DPE or SH only, yet partic-
ipants with CH and EEC are included in
the metformin pretreatment group
2. Exclusion bias as diabetic patients were
excluded, yet if pre-intervention blood glu-
cose values are assumed to be fasting, it is
likely that some individuals with undiag-
nosed diabetes were included. Inconsistent
exclusion of diabetic patients may have oc-
curred
CH: Complex Hyperplasia
DPE: Disordered Proliferative Endometrium
EEC: Endometrioid Endometrial Cancer
MA: Megestrol Acetate
PCOS: Polycystic Ovary Syndrome
SH: Simple Hyperplasia
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Campagnoli 2013 Wrong study design (review of role of metformin in endometrial pathology; not original study)
IRCT201412085563N6, 2015 Wrong study design (single-arm study; not blinded; no placebo or control)
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(Continued)
Legro 2007 Wrong patient population (patients with PCOS, not EH)
Mitsuhashi 2014 Wrong patient population (patients with preoperative endometrial cancer, not EH)
Mitsuhashi 2016 Wrong study design (patients with endometrial cancer used in second study arm instead of control
patients)
NCT01685762 Wrong study design (single-arm study)
NCT02035787, 2014 Wrong study design (single-arm, open-label study)
Perez-Lopez 2014 Wrong patient population (patients with endometrial cancer instead of patients with EH)
Randall 2014 Wrong study design (review of existing studies; no original data)
Shen 2008 Wrong study design (single-arm, non-blinded study)
Sivalingam 2015 Wrong outcomes (outcomes not measured histologically)
Sivalingam 2016 Wrong outcomes (outcomes not measured histologically)
Sivalingham 2015b Wrong outcomes (outcomes not measured histologically)
Zhou 2015 Wrong study design (no control arm)
EH: Endometrial Hyperplasia
PCOS: Polycystic Ovary Syndrome
Characteristics of ongoing studies [ordered by study ID]
IRCT201410275283N11
Trial name or title Comparison of metformin-megestrol acetate combination and megestrol acetate alone on endometrial his-
tology in patients with disordered proliferative or hyperplastic endometrium
Methods Randomised clinical trial
Participants Female patients with abnormal uterine bleeding and having disordered proliferative or hyperplastic en-
dometrium with or without atypia
Interventions Metformin 500 mg twice a day with megestrol 40 mg daily vs megestrol acetate 40 mg daily for 3 months
Outcomes Primary outcome
Endometrial pathology
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IRCT201410275283N11 (Continued)
Starting date 21 November 2014
Contact information Dr. Manizheh Sayyah-Melli, Tabriz, Iran; wrhrcenter@gmail.com
Notes Due to complete recruitment 30 April 2017
http://www.irct.ir/searchen.php?keyword=IRCT201410275283N11&field=a&lang=en
NCT01686126
Trial name or title Improving the treatment for women with early stage cancer of the uterus (feMMe)
Methods Randomised parallel-group open-label trial
Participants 1. Females with a BMI > 30 kg/m2 wishing to retain fertility, or females at high risk of surgical
complications owing to co-morbidities or obesity
2. Over 18 years of age at time of randomisation
3. Histologically confirmed complex endometrial hyperplasia with atypia or grade 1 endometrioid
endometrial adenocarcinoma on a curette or endometrial biopsy
4. CT or MRI scan of pelvis, abdomen, and chest (or chest x-ray) suggesting absence of extrauterine
disease
5. Myometrial invasion on MRI not greater than 50% for women with histologically confirmed
endometrial cancer only (for women who are unable to fit into an MRI machine, inclusion in trial is
decided at investigator’s discretion)
6. No lymph vascular invasion on curette or pipelle, if able to be assessed on sample
7. Serum CA125 ≤ 30 U/mL
8. No hypersensitivity or contraindications for Mirena
9. Ability to comply with endometrial biopsies at specified intervals
10. Negative serum or urine pregnancy test in premenopausal women and women < 2 years after onset of
menopause
11. Creatinine < 150 µmol/L (1.7 mg/dL) to be randomised into Mirena + Metformin arm (can still be
eligible to be randomised to Mirena only or Mirena + Weight loss (see Section 5.4, Other Eligibility Criteria
Considerations)
Interventions 1. Levonorgestrel (Mirena) 52 mg Intrauterine drug delivery system + Metformin
2. Levonorgestrel (Mirena) 52 mg Intrauterine drug delivery system
3. Levonorgestrel (Mirena) 52 mg Intrauterine drug delivery system + Weight loss
Outcomes Primary outcome
Pathological complete response
Secondary outcomes
1. Predicted response to treatment
2. Predicted response to treatment through blood and tissue molecular biomarkers
3. Increased molecular understanding of the biological pathogenesis of “early” EAC
Starting date October 2012
Contact information Vanessa L Taylor; vanessa.taylor3@health.qld.gov.au
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NCT01686126 (Continued)
Notes Study author correspondence: expected completion July 2019
https://clinicaltrials.gov/ct2/show/NCT01686126
NCT01968317
Trial name or title Megestrol acetate plus metformin to megestrol acetate in patients with endometrial atypical hyperplasia or
early stage endometrial adenocarcinoma
Methods Randomized parallel-group open-label trial
Participants 1. 18- to 45-year-old females
2. Primarily with confirmed diagnosis of endometrial atypical hyperplasia based upon D&C or hysteroscopy
OR primarily with confirmed diagnosis of endometrial adenocarcinoma (G1, low tumour grade) based upon
D&C or hysteroscopy, and 3 MRI parameters showing no myometrial invasion, extension beyond corpus,
or enlarged lymph nodes
3. Desire to retain reproductive function or uterus
4. Need to be able to undergo correlative treatment and follow-up
Interventions Megestrol acetate + Metformin or megestrol acetate alone
Outcomes Primary outcome
Pathological response rate
Secondary outcomes
1. Toxicity evaluation
2. Rate of relapse
3. Rate of pregnancy
Starting date October 2013
Contact information Xiaojun Chen; cxjlhjj@163.com
Notes Study author correspondence: trial recruited over 90 patients; expected completion at end of 2017
https://clinicaltrials.gov/ct2/show/NCT01968317
BMI: Body Mass Index
CT: Computed Tomography
D&C: Dilation & Curettage
EAC: Esophageal Adenocarcinoma
MRI: Magnetic Resonance Imaging
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D A T A A N D A N A L Y S E S
Comparison 1. Metformin versus megestrol acetate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Regression of endometrial
hyperplasia (with or without
atypia) towards normal
histology (defined here as
atrophic or proliferative
endometrium)
2 59 Odds Ratio (M-H, Fixed, 95% CI) 3.34 [0.97, 11.57]
2 Progression of endometrial
hyperplasia to endometrial
cancer
2 59 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Hysterectomy rate 2 61 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.05, 15.52]
4 Abnormal uterine bleeding 1 44 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.05, 15.52]
Comparison 2. Metformin plus megestrol acetate versus megestrol acetate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Regression of endometrial
hyperplasia (with or without
atypia) towards normal
histology (defined here
as proliferative/secretory
endometrium)
1 16 Odds Ratio (M-H, Fixed, 95% CI) 9.0 [0.94, 86.52]
2 Recurrence of endometrial
hyperplasia
1 8 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Progression of endometrial
hyperplasia to endometrial
cancer
1 16 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Hysterectomy rate 1 16 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 8.37]
5 Adverse effects during treatment Other data No numeric data
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Analysis 1.1. Comparison 1 Metformin versus megestrol acetate, Outcome 1 Regression of endometrial
hyperplasia (with or without atypia) towards normal histology (defined here as atrophic or proliferative
endometrium).
Review: Metformin for endometrial hyperplasia
Comparison: 1 Metformin versus megestrol acetate
Outcome: 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as atrophic or proliferative endometrium)
Study or subgroup Metformin Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sharifzadeh 2016 18/22 12/20 82.9 % 3.00 [ 0.74, 12.23 ]
Tabrizi 2014 10/11 4/6 17.1 % 5.00 [ 0.35, 71.90 ]
Total (95% CI) 33 26 100.0 % 3.34 [ 0.97, 11.57 ]
Total events: 28 (Metformin), 16 (Megestrol acetate)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours megestrol acetate Favours metformin
Analysis 1.2. Comparison 1 Metformin versus megestrol acetate, Outcome 2 Progression of endometrial
hyperplasia to endometrial cancer.
Review: Metformin for endometrial hyperplasia
Comparison: 1 Metformin versus megestrol acetate
Outcome: 2 Progression of endometrial hyperplasia to endometrial cancer
Study or subgroup Metformin Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sharifzadeh 2016 0/22 0/20 Not estimable
Tabrizi 2014 0/11 0/6 Not estimable
Total (95% CI) 33 26 Not estimable
Total events: 0 (Metformin), 0 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours metformin Favours megestrol acetate
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Analysis 1.3. Comparison 1 Metformin versus megestrol acetate, Outcome 3 Hysterectomy rate.
Review: Metformin for endometrial hyperplasia
Comparison: 1 Metformin versus megestrol acetate
Outcome: 3 Hysterectomy rate
Study or subgroup Metformin Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sharifzadeh 2016 1/23 1/21 100.0 % 0.91 [ 0.05, 15.52 ]
Tabrizi 2014 0/11 0/6 Not estimable
Total (95% CI) 34 27 100.0 % 0.91 [ 0.05, 15.52 ]
Total events: 1 (Metformin), 1 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours metformin Favours megestrol acetate
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Analysis 1.4. Comparison 1 Metformin versus megestrol acetate, Outcome 4 Abnormal uterine bleeding.
Review: Metformin for endometrial hyperplasia
Comparison: 1 Metformin versus megestrol acetate
Outcome: 4 Abnormal uterine bleeding
Study or subgroup Metformin Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sharifzadeh 2016 1/23 1/21 100.0 % 0.91 [ 0.05, 15.52 ]
Total (95% CI) 23 21 100.0 % 0.91 [ 0.05, 15.52 ]
Total events: 1 (Metformin), 1 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours metformin Favours megestrol acetate
Analysis 2.1. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 1
Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as
proliferative/secretory endometrium).
Review: Metformin for endometrial hyperplasia
Comparison: 2 Metformin plus megestrol acetate versus megestrol acetate
Outcome: 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as proliferative/secretory endometrium)
Study or subgroup Metformin + MA
Megestrol
acetate
(MA) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shan 2014 6/8 2/8 100.0 % 9.00 [ 0.94, 86.52 ]
Total (95% CI) 8 8 100.0 % 9.00 [ 0.94, 86.52 ]
Total events: 6 (Metformin + MA), 2 (Megestrol acetate (MA))
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours megestrol acetate Favours metformin + MA
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Analysis 2.2. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 2
Recurrence of endometrial hyperplasia.
Review: Metformin for endometrial hyperplasia
Comparison: 2 Metformin plus megestrol acetate versus megestrol acetate
Outcome: 2 Recurrence of endometrial hyperplasia
Study or subgroup Metformin + MA Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shan 2014 0/6 0/2 Not estimable
Total (95% CI) 6 2 Not estimable
Total events: 0 (Metformin + MA), 0 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours metformin + MA Favours megestrol acetate
Analysis 2.3. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 3
Progression of endometrial hyperplasia to endometrial cancer.
Review: Metformin for endometrial hyperplasia
Comparison: 2 Metformin plus megestrol acetate versus megestrol acetate
Outcome: 3 Progression of endometrial hyperplasia to endometrial cancer
Study or subgroup Metformin + MA Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shan 2014 0/8 0/8 Not estimable
Total (95% CI) 8 8 Not estimable
Total events: 0 (Metformin + MA), 0 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours metformin + MA Favours megestrol acetate
36Metformin for endometrial hyperplasia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.4. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 4
Hysterectomy rate.
Review: Metformin for endometrial hyperplasia
Comparison: 2 Metformin plus megestrol acetate versus megestrol acetate
Outcome: 4 Hysterectomy rate
Study or subgroup Metformin + MA Megestrol acetate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shan 2014 0/8 1/8 100.0 % 0.29 [ 0.01, 8.37 ]
Total (95% CI) 8 8 100.0 % 0.29 [ 0.01, 8.37 ]
Total events: 0 (Metformin + MA), 1 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours metformin + MA Favours megestrol acetate
Analysis 2.5. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 5
Adverse effects during treatment.
Adverse effects during treatment
Study
Shan 2014 3 patients in the metformin plus megestrol acetate group reported nausea that settled without medical treatment
A P P E N D I C E S
Appendix 1. Gynaecology and Fertility Specialised Register search strategy
From inception to 10 January 2017
Procite platform
Keywords CONTAINS “endometrial hyperplasia” or “endometrial proliferation” or “endometrial thickness” or “proliferation” or “hy-
perplasia” or Title CONTAINS “endometrial hyperplasia” or “endometrial proliferation” or “endometrial thickness” or “proliferation”
or “hyperplasia”
AND
Keywords CONTAINS “metformin” or “glucophage” or Title CONTAINS “metformin” or “glucophage”
(20 hits)
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Appendix 2. CENTRAL Register of Studies Online (CRSO) search strategy
Searched 10 January 2017
Web platform
#1MESH DESCRIPTOR Endometrial Hyperplasia EXPLODE ALL TREES 108
#2(Endometr* adj5 Hyperplas*):TI,AB,KY 373
#3(endometri* adj5 ?proliferat*):TI,AB,KY 109
#4#1 OR #2 OR #3446
#5MESH DESCRIPTOR Metformin EXPLODE ALL TREES 1777
#6metformin:TI,AB,KY 4409
#7glucophage:TI,AB,KY 32
#8(dimethylbiguanidine or dimethylguanylguanidine):TI,AB,KY 1
#9(dimethylbiguanidium or glucovance):TI,AB,KY 6
#10#5 OR #6 OR #7 OR #8 OR #9 4410
#11#4 AND #10 4
Appendix 3. MEDLINE search strategy
From 1946 to 10 January 2017
Ovid platform
1 exp Endometrial Hyperplasia/ (3592)
2 (endometri$ adj5 hyperplas$).tw. (4707)
3 (endometri$ adj3 ?proliferat$).tw. (2820)
4 or/1-3 (8286)
5 exp Metformin/ (11182)
6 metformin.tw. (15758)
7 glucophage.tw. (110)
8 (dimethylbiguanidine or dimethylguanylguanidine).tw. (4)
9 (dimethylbiguanidium or glucovance).tw. (18)
10 or/5-9 (17514)
11 4 and 10 (51)
12 randomized controlled trial.pt. (507659)
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13 controlled clinical trial.pt. (98156)
14 randomized.ab. (438219)
15 randomised.ab. (87256)
16 placebo.tw. (209885)
17 clinical trials as topic.sh. (197782)
18 randomly.ab. (298723)
19 trial.ti. (201663)
20 (crossover or cross-over or cross over).tw. (79922)
21 or/12-20 (1280596)
22 exp animals/ not humans.sh. (4853032)
23 21 not 22 (1182904)
24 11 and 23 (4)
Appendix 4. Embase search strategy
From 1980 to 10 January 2017
Ovid platform
1 exp endometrium hyperplasia/ (6938)
2 (endometri$ adj5 hyperplas$).tw. (5824)
3 (endometri$ adj3 proliferat$).tw. (3376)
4 or/1-3 (11242)
5 exp metformin/ (47713)
6 metformin.tw. (23994)
7 glucophage.tw. (1571)
8 (dimethylbiguanidine or dimethylguanylguanidine).tw. (4)
9 (dimethylbiguanidium or glucovance).tw. (195)
10 or/5-9 (48540)
11 4 and 10 (138)
12 Clinical Trial/ (1019530)
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13 Randomized Controlled Trial/ (472724)
14 exp randomization/ (84526)
15 Single Blind Procedure/ (28735)
16 Double Blind Procedure/ (138900)
17 Crossover Procedure/ (54650)
18 Placebo/ (326024)
19 Randomi?ed controlled trial$.tw. (153072)
20 Rct.tw. (23004)
21 random allocation.tw. (1649)
22 randomly.tw. (343380)
23 randomly allocated.tw. (26969)
24 allocated randomly.tw. (2221)
25 (allocated adj2 random).tw. (847)
26 Single blind$.tw. (18934)
27 Double blind$.tw. (174826)
28 ((treble or triple) adj blind$).tw. (672)
29 placebo$.tw. (250674)
30 prospective study/ (394570)
31 or/12-30 (2008326)
32 case study/ (94777)
33 case report.tw. (327043)
34 abstract report/ or letter/ (994732)
35 or/32-34 (1407253)
36 31 not 35 (1956293)
37 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5761760)
38 36 not 37 (1831795)
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39 11 and 38 (41)
Appendix 5. CINAHL search strategy
From 1961 to 10 January 2017
Ebsco platform
1. (MM “Endometrial Diseases+”) 3,905
2. TX (endometr* N5 hyperplas*) 329
3. TX (endometr* N3 proliferat*) 111
4. 1 OR 2 OR 3 4,184
5. (MM “Metformin”) 1,959
6. TX Metformin 5,076
7. TX glucophage 36
8. TX (dimethylbiguanidium or glucovance) 6
9. 5 OR 6 OR 7 OR 8 5,080
10. 4 AND 9 18
Appendix 6. PubMed search strategy
Searched 10 January 2017
Web platform
1. Endometrial Hyperplasia[mh]
2. (endometri* and hyperplas*)[tw]
3. (endometri* and proliferat*)[tw]
4. or/1-3
5. Metformin[mh]
6. metformin[tw]
7. glucophage[tw]
8. (dimethylbiguanidine or dimethylguanylguanidine)[tw]
9. (dimethylbiguanidium or glucovance)[tw]
10. or/5-9
11. 4 and 10
12. randomized controlled trial[ptyp]
13. controlled clinical trial[ptyp]
14. randomized[tw]
15. randomized[tw]
16. placebo[tw]
17. randomly[tw]
18. trial[tw]
19. (crossover or cross-over or cross over)[tw]
20. or/12-20
21. animals[mh] not humans[mh]
22. 20 not 21
23. 11 and 22
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Appendix 7. Google Scholar search strategy
Searched 10 January 2017
Web platform
Keywords include: “endometrium”, “endometrial”, “hyperplasia, ”proliferation“, ”metformin“
Appendix 8. ClinicalTrials.gov search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
Appendix 9. World Health Organization International Trials Registry Platform search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
Appendix 10. OpenGrey search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
Appendix 11. LILACS search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
C O N T R I B U T I O N S O F A U T H O R S
WA and NC initiated the review; NC, TO, and HS drafted and finalised the background and objectives; JS, TO, and HS drafted and
finalised the methods sections with assistance from CM. WA reviewed the final protocol. HS performed all searches. NC, TO, JS, and
HS then screened titles and abstracts for potential inclusion. Two of NC, TO, JS, and HS assessed each paper for potential inclusion.
JS performed searches of unpublished trials and contacted relevant authors. NC, TO, HS, and JS extracted data from included studies,
with WA providing clinical interpretation of data. NC, TO, HS, JS, and CM drafted the review, and WA reviewed the final draft.
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D E C L A R A T I O N S O F I N T E R E S T
WA is a Clinical Associate Professor and a Consultant Gynaecologist at Queen’s Medical Centre, at Nottingham, in the UK. He
previously submitted an application to the Nottingham Clinical Trials Unit (in the process of developing a research grant application
to the UK NIHR) to conduct a clinical trial comparing metformin with progesterone for treatment of endometrial hyperplasia. A
systematic review was suggested to support the trial.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support, UK.
External sources
• No sources of support, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. In the protocol, we stated that for the outcomes regression of endometrial hyperplasia and progression to endometrial
carcinoma, we would calculate Mantel-Haenszel odds ratios. In the review, we have added that if data are available, we will (in
preference) calculate hazard ratios for the outcomes regression of endometrial hyperplasia, recurrence of endometrial hyperplasia, and
progression to endometrial carcinoma, as hazard ratios include participants who dropped out of the study and therefore provide the
best way to analyse these outcomes.
2. In the protocol, our objective was ”To determine the efficacy and safety of metformin in treating women with endometrial
hyperplasia.“ Upon editorial recommendation, we have changed this to ”To determine the effectiveness and safety of metformin in
treating women with endometrial hyperplasia.“
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